Some studies have shown that ERCC1, ERCC2, and XRCC1 polymorphisms may influence the clinical outcome in CRC patients treated with adjuvant [20] or palliative oxaliplatin-based chemotherapy [21, 22]. This evidence concerns the gene XRCC1 and colorectal carcinoma.